Skip to content
News Center
About Us Careers News Center Contact Us Legal Video Hub iHope Doing Business with Illumina Investors Illumina for Startups Home

Press Releases

Date Title
Jun 24, 2024 Illumina completes the divestiture of GRAIL
Jun 11, 2024 Illumina DRAGEN v4.3 powers most comprehensive, accurate genome with industry-leading innovations
Jun 4, 2024 Illumina launches latest chemistry across most popular mid-throughput sequencers, enabling higher quality and greater speed for customers at lower cost
Jun 3, 2024 Illumina Board of Directors approves spin-off of GRAIL; declares spin-off dividend of GRAIL shares
Jun 3, 2024 Illumina appoints Everett Cunningham Chief Commercial Officer
May 29, 2024 Illumina drives genomic testing as standard of care in oncology through collaborative research presented at ASCO
May 28, 2024 Illumina releases 2023 Corporate Social Responsibility Report
May 20, 2024 Anna Richo joins Illumina's Board of Directors
May 15, 2024 Illumina To Webcast Upcoming Investor Conference
May 6, 2024 Illumina publicly files Form 10 registration statement ahead of planned divestiture of GRAIL
May 3, 2024 Illumina To Webcast Upcoming Investor Conference
May 2, 2024 Illumina Reports Financial Results for First Quarter of Fiscal Year 2024
Apr 12, 2024 Illumina's planned divestment of GRAIL approved by the European Commission
Apr 9, 2024 Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer
Apr 4, 2024 Illumina to Announce First Quarter 2024 Financial Results on Thursday, May 2, 2024
Feb 8, 2024 Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2023
Jan 9, 2024 Illumina Announces Preliminary Financial Results for Fourth Quarter and Fiscal Year 2023
Jan 5, 2024 Illumina expands collaboration with Janssen to advance molecular residual disease cancer test
Jan 4, 2024 Illumina to Announce Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 8, 2024
Jan 4, 2024 The Alliance for Genomic Discovery welcomes Bristol Myers Squibb, GSK, and Novo Nordisk
For Research Use Only

Not for use in diagnostic procedures (except as specifically noted).

Innovative technologies

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

All trademarks are the property of Illumina, Inc. or their respective owners.
For specific trademark information, see www.illumina.com/company/legal.html.

© 2024 Illumina, Inc. All rights reserved.